HIV-1 tat Disrupts CX3Cl1-CX3CR1 Axis in Microglia via the NF-κBYY1 pathway

Current HIV Research

Volumn 12, Issue 3, 2014, Pages 189-200

  Duan, Ming ^a   Yao, Honghong ^c   Cai, Yu ^b   Liao, Ke ^b   Seth, Pankaj ^d   Buch, Shilpa ^b  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^d National Brain Research Center   (India)

Author keywords

CX3CL1; CX3CR1; HIV 1 tat protein; Microglia; NF B; YY1

Indexed keywords

BETA ACTIN; CALCIUM; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR YY1; TUMOR NECROSIS FACTOR ALPHA; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, HUMAN; CX3CR1 PROTEIN, HUMAN; YY1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE REPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MICROGLIA; MICROSCOPY; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; GENE EXPRESSION PROFILING; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VIROLOGY;

ANIMALS; CELLS, CULTURED; CHEMOKINE CX3CL1; DOWN-REGULATION; GENE EXPRESSION PROFILING; HIV-1; HUMANS; MICROGLIA; NF-KAPPA B; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHEMOKINE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; YY1 TRANSCRIPTION FACTOR;

EID: 84906245609     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X12666140526123119     Document Type: Article

References (53)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-99.
2. Yadav A. Collman RG CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol 2009; 4: 430-47.
3. Bansal AK, Mactutus CF, Nath A, et al. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res 2000; 879: 42-9.
4. Hudson L, Liu J, Nath A, et al. Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 2000; 6: 145-55.
5. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11: 1421-31.
6. Bruce-Keller AJ, Barger SW, Moss NI, et al. Pro-inflammatory and pro-oxidant properties of the HIV protein Tat in a microglial cell line: attenuation by 17 beta-estradiol. J Neurochem 2001; 78: 1315-24.
7. Polazzi E, Levi G, Minghetti L. Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures. J Neuropathol Exp Neurol 1999; 58: 825-31.
8. Turchan-Cholewo J, Dimayuga FO, Gupta S, et al. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 2009; 108: 202-15.
9. Minghetti L, Visentin S, Patrizio M, et al. Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem Res 2004; 29: 965-78.
10. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998; 95: 10896-901.
11. Limatola C, Lauro C, Catalano M, et al. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol 2005;166: 19-28.
12. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917-24.
13. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-4.
14. Sechler JM, Barlic J, Grivel JC, Murphy PM. IL-15 alters expression and function of the chemokine receptor CX3CR1 in human NK cells. Cell Immunol 2004; 230: 99-108.
15. Barlic J, Sechler JM, Murphy PM. IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1. Blood 2003; 102: 3494-503.
16. Saitoh Y, Koizumi K, Sakurai H, Minami T, Saiki I. RANKLinduced down-regulation of CX3CR1 via PI3K/Akt signaling pathway suppresses Fractalkine/CX3CL1-induced cellular responses in RAW264.7 cells. Biochem Biophys Res Commun 2007; 364: 417-22.
17. Corona AW, Huang Y, O'Connor JC, et al. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. J Neuroinflammation 2010; 7: 93.
18. Boddeke EW, Meigel I, Frentzel S, et al. Functional expression of the fractalkine (CX3C) receptor and its regulation by lipopolysaccharide in rat microglia. Eur J Pharmacol 1999; 374: 309-13.
19. Wynne AM, Henry CJ, Huang Y, Cleland A, Godbout JP. Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge. Brain Behav Immun 2010; 24: 1190-201.
20. Suzuki M, El-Hage N, Zou S, et al. Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. Mol Neurodegener 2011; 6: 78.
21. Wu S, Hu YC, Liu H, Shi Y. Loss of YY1 impacts the heterochromatic state and meiotic double-strand breaks during mouse spermatogenesis. Mol Cell Biol 2009; 29: 6245-56.
22. Wang H, Garzon R, Sun H, et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14: 369-81.
23. Chao CC, Gekker G, Hu S, Peterson PK. Human microglial cell defense against Toxoplasma gondii. The role of cytokines. J Immunol 1994; 152: 1246-52.
24. Miller AM, Stella N. Microglial cell migration stimulated by ATP and C5a involve distinct molecular mechanisms: quantification of migration by a novel near-infrared method. Glia 2009; 57: 875-83.
25. Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG. Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology. J Neurosci 2009; 29: 3-13.
26. Swingler S, Morris A, Easton A. Tumour necrosis factor alpha and interleukin-1 beta induce specific subunits of NFKB to bind the HIV-1 enhancer: characterisation of transcription factors controlling human immunodeficiency virus type 1 gene expression in neural cells. Biochem Biophys Res Commun 1994; 203: 623-30.
27. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, et al. NFkappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007; 27: 4374-87.
28. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB. Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 1999; 163: 1628-35.
29. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A 2000; 97: 8075-80.
30. Cambien B, Pomeranz M, Schmid-Antomarchi H, Millet MA, Breittmayer V, et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood 2001; 97: 2031-37.
31. Noda M, Doi Y, Liang J, Kawanokuchi J, et al. Fractalkine attenuates excito-neurotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxygenase-1 expression. J Biol Chem 2011; 286: 2308-19.
32. Chen S, Luo D, Streit WJ, Harrison JK. TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia. J Neuroimmunol 2002; 133: 46-55.
33. Zhang M, Xu G, Liu W, Ni Y, Zhou W. Role of fractalkine/CX3CR1 interaction in light-induced photoreceptor degeneration through regulating retinal microglial activation and migration. PLoS One 2012; 7: e35446.
34. Cirone M, Conte V, Farina A, Valia S, Trivedi P, et al. HHV-8 reduces dendritic cell migration through down-regulation of cellsurface CCR6 and CCR7 and cytoskeleton reorganization. Virol J 2012; 9: 92.
35. Schwartzkopff F, Petersen F, Grimm TA, Brandt E. CXC chemokine ligand 4 (CXCL4) down-regulates CC chemokine receptor expression on human monocytes. Innate Immun 2012; 18: 124-39.
36. Ehlin-Henriksson B, Liang W, Cagigi A, et al. Changes in chemokines and chemokine receptor expression on tonsillar B cells upon Epstein-Barr virus infection. Immunology 2009; 127: 549-57.
37. Hundhausen C, Misztela D, Berkhout TA, et al. The disintegrinlike metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102: 1186-95.
38. Ramos MV, Fernandez GC, Brando RJ, et al. Interleukin-10 and interferon-gamma modulate surface expression of fractalkinereceptor (CX(3)CR1) via PI3K in monocytes. Immunology 2010; 129: 600-09.
39. Pachot A, Cazalis MA, Venet F, et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol 2008; 180: 6421-9.
40. Bethel-Brown C, Yao H, Callen S, et al. HIV-1 Tat-mediated induction of platelet-derived growth factor in astrocytes: role of early growth response gene 1. J Immunol 2008; 186: 4119-29.
41. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation 2011; 8: 9.
42. Cho SH, Sun B, Zhou Y, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaqueindependent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 2011; 286: 32713-22.
43. Briones TL, Woods J, Wadowska M. Chronic neuroinflammation and cognitive impairment following transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling. J Neuroinflammation 2014; 11: 13.
44. Fumagalli S, Perego C, Ortolano F, De Simoni MG. CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia 2013; 61: 827-42.
45. Cipriani R, Villa P, Chece G, et al. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci 2011; 31: 16327-35.
46. Tang Z, Gan Y, Liu Q, et al. CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. J Neuroinflammation 2014; 11: 26.
47. Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-14.
48. Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005; 8: 752-758.
49. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008; 28: 1707-21.
50. Donnelly DJ, Longbrake EE, Shawler TM, et al. Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J Neurosci 2011; 31: 9910-22.
51. McManus CM, Weidenheim K, Woodman SE, et al. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. Am J Pathol 2000; 156: 1441-53.
52. D'Aversa TG, Yu KO, Berman JW. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J Neurovirol 2004; 10: 86-97.
53. Li W, Li G, Steiner J, Nath A. Role of Tat protein in HIV neuropathogenesis. Neurotox Res 2009; 16: 205-220.